ImmunityBio Secures Exclusive U.S. Rights to Tokyo-Strain BCG for Bladder Cancer Treatment
ImmunityBio Inc. has entered an exclusive agreement with Japan BCG Laboratory to develop and commercialize the Tokyo strain of Bacillus Calmette-Guérin (BCG) in the United States, following positive Phase 3 trial results showing non-inferiority compared to TICE BCG for high-grade bladder cancer treatment.
Tickers: $IBRX
Topics: BCG therapy biotech bladder cancer treatment FDA regulatory pathway